July 8, 2025
Contact:
Andarix Pharmaceuticals
617-957-9858
info@andarix.com
Targeted Peptide Therapy and Pioneering Cancer Clinical Trials Featured at Upcoming Event
Boston, MA — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapies for rare cancers, announced today that CEO Chris Adams will deliver a keynote presentation at the Clinical Trials in Oncology Conference, taking place July 8–9, 2025, in Boston, Massachusetts. This pivotal event will focus on accelerating cancer clinical trials and innovative strategies to address unmet needs in cancer research, with special emphasis on rare and difficult-to-treat cancers.
Industry experts, clinical operations professionals, and patient advocacy groups are set to attend, reflecting the conference’s broad relevance to both common and rare cancer trial communities. Mr. Adams will share updates on Andarix Pharmaceuticals’ cancer-focused clinical trial programs, detail the company’s experience designing trials for rare cancer indications, and discuss best practices for enhancing patient recruitment and regulatory engagement.
Key Topics of the Conference
- Innovations in Cancer Clinical Trials:
Latest methods in trial design, including adaptive protocols and biomarker-driven enrollment for cancer therapies. - Challenges in Rare Cancer Clinical Research:
Strategies for overcoming patient recruitment barriers, building robust registries, and engaging with diverse research communities. - Collaboration with Patient Advocacy Groups:
Fostering early and continuous involvement of patients to improve trial outcomes and retention. - Regulatory and Operational Excellence:
Importance of early regulatory planning and cross-stakeholder communication to efficiently bring novel cancer therapies to market.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized cancer therapies, advancing platforms that combine diagnostic imaging agents for patient selection and targeted peptide therapeutics. The company’s lead programs employ a proprietary somatostatin peptide conjugate, which leverages the overexpression of somatostatin receptors on solid tumors—most notably lung, neuroendocrine, and pancreatic cancers. Andarix’s technology and early-phase clinical development efforts are aimed at meeting the critical needs of patients with limited treatment options, and the results from these cancer clinical trials are informing the next generation of precision therapies.
To learn more about Andarix Pharmaceuticals and its clinical trial programs, please visit www.andarix.com.